BREAKING NEWS: US BioTek Laboratories has officially completed its merger with NutriPATH Pathology as of March 3, 2026, a monumental development in the global functional laboratory industry. This partnership, announced today, combines the strengths of both organizations, enhancing their ability to provide comprehensive and clinically actionable testing to healthcare providers around the world.
The merger signifies a major step forward for both companies, expanding their international presence while reinforcing their commitment to scientific rigor and clinical relevance. US BioTek Laboratories, based in Seattle, is renowned for its expertise in immunological testing, including food sensitivity and specialty biomarker assessments. Meanwhile, NutriPATH Pathology, located in Melbourne, Australia, is respected for its functional pathology services, particularly in gut health and nutritional assessment.
Jack Frausing, CEO of US BioTek Laboratories, stated, “This merger marks an exciting new chapter for both US BioTek and NutriPATH. Our shared philosophy centers on providing clinicians with meaningful data they can trust and apply in practice.” This alignment aims to empower healthcare practitioners with deeper insights and more innovative testing solutions.
In a joint statement, James Cavaggion, CEO of NutriPATH, along with directors Mary Cavaggion and Andrew Cavaggion, emphasized, “This is more than a combination of two companies — it is a strategic alignment of values, scientific expertise, and a mutual dedication to advancing functional medicine globally.” This sentiment underscores the broader impact of the merger on the field of functional medicine.
The merger allows NutriPATH Pathology to maintain its established brand presence in Australia, ensuring continuity for its practitioners while gaining access to additional resources and technologies that will enhance clinical support and scientific collaboration.
Both organizations are committed to a seamless transition for their clients, ensuring ongoing service excellence during this pivotal time. This merger not only strengthens their operational capabilities but also expands their portfolio of testing solutions, ultimately benefiting healthcare providers focused on personalized, root-cause-focused care.
As the functional laboratory industry evolves, this merger represents a significant milestone that will likely influence diagnostics and patient care practices worldwide. Stakeholders in the healthcare community are encouraged to stay tuned for further updates on how this merger will enhance testing capabilities and clinical outcomes.
For more information, visit US BioTek Laboratories and NutriPATH Pathology’s official websites or follow their social media channels for the latest developments. This merger is poised to redefine standards in functional and integrative healthcare, and the impact will be felt across the industry.
